Literature DB >> 3617504

Biosynthesis and phosphorylation of vaccinia virus structural protein VP11.

S Y Kao, W R Bauer.   

Abstract

One of the major DNA binding proteins contained in vaccinia virus is an 11-kDA species denoted VP11. The biosynthesis of VP11, a late polypeptide, occurs subsequent to the initiation of viral DNA replication. In particular, VP11 synthesis is blocked by cytosine arabinoside, a specific inhibitor of DNA synthesis. We show here that VP11 is specifically phosphorylated subsequent to translation. Phosphorylated VP11 is present both in viral core particles and in the cytoplasm of virus-infected cells. Kinetic analysis reveals that the total amount of phosphorylated VP11 species increases rapidly and remains approximately constant for as long as 17 hr postinfection. Phosphorylation occurs at two different serine residues, progressing from either site singly to the diphosphorylated product. Under steady-state conditions, the phosphorylated derivative constitutes approximately 85% of total VP11 in extracts of vaccinia virus-infected cells. Even though 15% of the VP11 remains unphosphorylated in cell extracts, only phosphorylated VP11 is found in mature viral cores.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3617504     DOI: 10.1016/0042-6822(87)90479-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

1.  Genetic analysis of the vaccinia virus I6 telomere-binding protein uncovers a key role in genome encapsidation.

Authors:  Olivera Grubisha; Paula Traktman
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Investigation of structural and functional motifs within the vaccinia virus A14 phosphoprotein, an essential component of the virion membrane.

Authors:  Jason Mercer; Paula Traktman
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Structure/Function analysis of the vaccinia virus F18 phosphoprotein, an abundant core component required for virion maturation and infectivity.

Authors:  Nadi T Wickramasekera; Paula Traktman
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

4.  Identification of the major membrane and core proteins of vaccinia virus by two-dimensional electrophoresis.

Authors:  O N Jensen; T Houthaeve; A Shevchenko; S Cudmore; T Ashford; M Mann; G Griffiths; J Krijnse Locker
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  DNA packaging mutant: repression of the vaccinia virus A32 gene results in noninfectious, DNA-deficient, spherical, enveloped particles.

Authors:  M C Cassetti; M Merchlinsky; E J Wolffe; A S Weisberg; B Moss
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  The Vaccinia virus E8R gene product: a viral membrane protein that is made early in infection and packaged into the virions' core.

Authors:  Laura Doglio; Ario De Marco; Sibylle Schleich; Norbert Roos; Jacomine Krijnse Locker
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Vaccinia virus morphogenesis is interrupted when expression of the gene encoding an 11-kilodalton phosphorylated protein is prevented by the Escherichia coli lac repressor.

Authors:  Y F Zhang; B Moss
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  Vaccinia virus temperature-sensitive mutants in the A28 gene produce non-infectious virions that bind to cells but are defective in entry.

Authors:  Peter C Turner; Bradley P Dilling; Cindy Prins; Steven G Cresawn; Richard W Moyer; Richard C Condit
Journal:  Virology       Date:  2007-05-17       Impact factor: 3.616

9.  Transcription of viral late genes is dependent on expression of the viral intermediate gene G8R in cells infected with an inducible conditional-lethal mutant vaccinia virus.

Authors:  Y Zhang; J G Keck; B Moss
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

10.  Functional characterization of the vaccinia virus I5 protein.

Authors:  Bethany Unger; R Jeremy Nichols; Eleni S Stanitsa; Paula Traktman
Journal:  Virol J       Date:  2008-12-15       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.